ImageneBio Stock (NASDAQ:IMA)

Forecast Financials Chart

Previous Close

$8.00

52W Range

$7.24 - $23.28

50D Avg

$9.55

200D Avg

$14.23

Market Cap

$93.37M

Avg Vol (3M)

$62.03K

Beta

0.41

Div Yield

-

IMA Company Profile

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

10

IPO Date

Feb 27, 1998

Website

IMA Performance

IMA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	$9.16M	$15.62M
Operating Income	$-58.97M	$-75.42M	$-70.90M
Net Income	$-49.23M	$-68.17M	$-68.77M
EBITDA	$-48.59M	$-74.40M	$-70.15M
Basic EPS	$-1.02	$-1.63	$-1.90
Diluted EPS	$-1.02	$-1.63	$-1.90

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
KLRS	Kalaris Therapeutics Inc
HYFT	MindWalk Holdings Corp.
IFRX	InflaRx N.V.
NTRB	Nutriband Inc.
IMUX	Immunic, Inc.
ACET	Adicet Bio, Inc.
VXRT	Vaxart, Inc.
UNCY	Unicycive Therapeutics, Inc.
STTK	Shattuck Labs, Inc.